<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        4-949-16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CLARINASE TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PSEUDOEPHEDRINE HYDROCHLORIDE,LORATADINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        120,5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        OTC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        18.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SAG Manufacturing SLU" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SAG Manufacturing SLU
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2947]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Bayer Saudi Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BAYER CONSUMER CARE AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R06AX13
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        R01BA52
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Clarinase Repetabs contains a combination of two medicines (loratadine and pseudoephedrine<br />sulphate). Loratadine is an antihistamine and pseudoephedrine sulphate is a decongestant.<br /><strong>How Clarinase Repetabs works</strong><br />Clarinase Repetabs help to reduce your allergy or common cold symptoms by stopping the effects of<br />a substance called &laquo;histamine&raquo;, which is produced by the body when you are allergic to something.<br />Decongestants help to clear nasal congestion.<br /><strong>When Clarinase Repetabs should be used</strong><br />Clarinase Repetabs relieve symptoms associated with seasonal allergic rhinitis (hay fever), such as,<br />sneezing, runny or itchy nose, and eyes, when accompanied by nasal congestion in adults and children<br />12 years of age and over.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Do not take Clarinase Repetabs if</strong><br />- you are allergic (hypersensitive) to loratadine, pseudoephedrine or to any of the other ingredients of<br />this medicine (listed in section 6).<br /><strong>Due to the presence of pseudoephedrine, do not take Clarinase Repetabs if</strong><br />- you are also receiving heart or blood pressure medicine.<br />- you have glaucoma, difficulty in urinating, urinary tract blockage, high blood pressure, heart or blood<br />vessel disease, a history of stroke, or an overactive thyroid.<br />- you are receiving monoamine oxidase (MAO) inhibitor therapy or have stopped taking this medicine<br />within the last 14 days.<br /><strong>Warnings and precautions</strong><br />Certain conditions may make you unusually sensitive to the decongestant pseudoephedrine contained<br />in this medicine.<br />Talk to your doctor or pharmacist before taking Clarinase Repetabs if<br />- you are 60 years of age or older, Older adults may be more sensitive to the effects of this medicine<br />- you have diabetes mellitus (sugar diabetes), stenosing peptic ulcer (ulcer leading to the narrowing of<br />the stomach, small intestine or esophagus), pyloroduodenal blockage (intestine blockage), blockage of<br />Clarinase&reg; 0</p><p dir="ltr">the vesical cervix (bladder neck blockage), previous history of bronchospasm (difficulty breathing due<br />to tightening of the lung muscles), or problems with your liver, kidney, or bladder.<br />- you are scheduled to have surgery, because you may have to stop taking Clarinase Repetabs for a few<br />days.<br />- you are taking digitalis, a medicine used to treat certain heart disorders, because the dosage may have<br />to be adjusted.<br />- you are taking &alpha;-methyldopa, mecamylamine, reserpine, veratrum alkaloids and guanethidine for<br />blood pressure, because the dose may need to be adjusted.<br />- you are taking decongestants (oral or nasal), appetite suppressants (diet pills), or amphetamines,<br />because together with Clarinase Repetabs, these medications may raise your blood pressure.<br />- you are taking ergot alkaloids (such as dihydroergotamine, ergotamine, or methylergometrine) for<br />migraines. Together with Clarinase Repetabs, these medications may raise your blood pressure.<br />- you are taking linezolide (an antibiotic), bromocriptine (for infertility or Parkinson&rsquo;s disease),<br />cabergoline, lisuride and pergolide (for Parkinson&rsquo;s disease). Together with Clarinase Repetabs, this<br />medication may raise your blood pressure.<br />- you are taking antacids, because they may increase the effectiveness of Clarinase Repetabs.<br />- you are taking kaolin, because it may lower the effectiveness of Clarinase Repetabs.<br />- you are scheduled to have skin tests for allergies you should not take Clarinase Repetabs for two days<br />before having these tests, because this medicine may affect test results.<br />Tell your doctor if you experience or are diagnosed with any of the following:<br />&bull; high blood pressure,<br />&bull; a fast or pounding heartbeat,<br />&bull; abnormal heart rhythm,<br />&bull; feeling sick and headache or increase headache while using Clarinase Repetabs. Your doctor may<br />advise you to stop your treatment.<br />One of the medicines in Clarinase Repetabs, pseudoephedrine sulphate, has the potential to be abused<br />and large doses of pseudoephedrine sulphate can be toxic.<br />Acute generalized exanthematous pustulosis (AGEP),<strong> a form of severe skin reaction</strong>, may occur with<br />pseudoephedrine-containing products in <strong>isolated cases</strong>. If signs and symptoms such as fever, erythema,<br />or small (generalized) pustules are observed, you should discontinue to use the drug and consult your<br />physician.<br /><strong>Children</strong><br />Do not give this medicine to children less than 12 years of age.<br /><strong>Other medicines and Clarinase Repetabs</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.<br />This includes medicines obtained without a prescription.<br /><strong>Clarinase Repetabs with alcohol</strong><br />Clarinase Repetabs has not been shown to add to the effects of an alcoholic drink.<br /><strong>Pregnancy, breast-feeding and fertility</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask<br />your doctor or pharmacist for advice before taking this medicine.<br /><strong>Pregnancy</strong><br />Do not take Clarinase Repetabs if you are pregnant.<br /><strong>Breast-feeding</strong><br />Do not take Clarinase Repetabs if you are breast-feeding.<br />Loratadine and pseudoephedrine are excreted in breast milk. Decreased milk production in nursing<br />mothers has been reported with pseudoephedrine, a component of Clarinase Repetabs.<br /><strong>Driving and using machines</strong><br />At the recommended dose, Clarinase Repetabs is not expected to cause you to be drowsy or less alert.<br />However, very rarely some people experience drowsiness, which may affect their ability to drive or use<br />machines.<br /><strong>Clarinase Repetabs contain lactose and sucrose</strong><br />Clarinase Repetabs prolonged-release tablets contain lactose and sucrose; thus if you have been told<br />by your doctor that you have an intolerance to some sugars, contact your doctor before taking this<br />medicine.<br /><strong>Laboratory tests</strong><br />Athletes taking Clarinase Repetabs may have positive doping-tests.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or<br />pharmacist if you are not sure.<br /><strong>How much to take:</strong><br /><strong>Adults and adolescents 12 years of age and over</strong><br />The recommended dose is one Clarinase Repetabs prolonged-release tablet <strong>twice</strong> daily with a glass of<br />water, with or without food.<br />This medicine is for oral use.<br />Swallow the tablet whole; do not crush, break or chew the tablet before swallowing.<br />Do not take more Clarinase Repetabs than recommended on the label or take tablets more often than<br />recommended.<br />Do not take this medicine for more than 10 days continuously unless your doctor tells you to do so.<br /><strong>If you take more Clarinase Repetabs than you should</strong><br />If you take an overdose, tell your doctor or pharmacist straight away. Sleepiness, rapid heartbeat and<br />headache have been reported with overdoses of loratadine, a component of Clarinase Repetabs.<br />Convulsions, rapid heartbeat, nausea and nervousness have been reported with overdoses of<br />pseudoephedrine, a component of Clarinase Repetabs.<br /><strong>If you forget to take Clarinase Repetabs</strong><br />- If you forget to take your dose, take it as soon as you remember, then continue to take it as usual.<br />- Do not take a double dose to make up for a forgotten dose.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, this medicine can cause side effects, although not everybody gets them. Contact<br />a doctor or pharmacist immediately if you have any reaction to Clarinase Repetabs that continues, is<br />bothersome or that you think is serious.<br />Very common side effects (may affect more than 1 in 10 people) associated with Clarinase Repetabs 5<br />mg/120 mg prolonged-release tablets include: trouble sleeping.<br />Common side effects (may affect up to 1 in 10 people) associated with Clarinase Repetabs 5 mg/120<br />mg prolonged-release tablets include: thirst, nervousness, drowsiness, depression, agitation, anorexia,<br />dizziness, dry mouth, fast heartbeat, sore throat, inflammation of the nasal lining, constipation, nausea,<br />headache and tiredness.<br />Side effects occurring less frequently include: confusion, tremor, increased sweating, hot flushes, altered<br />taste, abnormal tearing of the eyes, ringing in the ears, irregular heartbeat, nosebleed, frequent or<br />abnormal urination and itching.<br />From post-marketing experience, isolated cases of acute generalized exanthematous pustulosis (AGEP),<br />a form of severe skin reaction, have been reported with pseudoephedrine-containing products.<br />The following <strong>very rare</strong> side effects (may affect up to 1 in 10,000 people) have also been seen during the<br />marketing of Clarinase Repetabs: severe allergic reaction including rash, hives, and swelling of the face,<br />vertigo, convulsions, abnormal heart rhythms, high blood pressure, cough, narrowing of the airways,<br />liver problems, difficulty urinating, and hair loss have been reported.</p><p dir="ltr">Other adverse reactions that were only reported for loratadine in clinical trials and during the post-<br />marketing period include increased appetite, rash and upset stomach.</p><p dir="ltr"><strong>Reporting of side effects</strong><br />If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not<br />listed in this leaflet. By reporting side effects you can help provide more information on the safety of this<br />medicine.<br /><strong>To report any side effect(s)<br />The National Pharmacovigilance Centre (NPC):<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa/</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">- Keep this medicine out of the sight and reach of children.<br />- Do not store above 25&deg;C. Store in the original package in order to protect from moisture. Do not freeze.<br />- Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The<br />expiry date refers to the last day of that month.<br />- Do not use this medicine if you notice any change in the appearance of the tablets.<br />- Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to<br />throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>What Clarinase Repetabs contains</strong><br />- The active substances in Clarinase Repetabs prolonged-release tablets are loratadine 5 mg and<br />pseudoephedrine sulphate 120 mg.<br />- The other ingredients are: core &ndash; lactose monohydrate; maize starch; povidone; and magnesium<br />stearate; coating &ndash; acacia; calcium sulphate anhydrous; calcium sulphate dihydrate; carnauba wax;<br />microcrystalline cellulose; oleic acid; colophonium; soap powder; sucrose; talc; titanium dioxide; white<br />beeswax; and zein.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Clarinase Repetabs 5 mg/120 mg are round, white, prolonged-release tablets. They are available in
blister strips in pack sizes of 1, 7, 10, 14, 20, 28, 30, 50 and 100 tablets.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Bayer Consumer Care AG,<br />Basel - Switzerland.<br /><strong>Manufactured &amp; Released by:</strong><br />SAG Manufacturing SLU, San Agustin de Guadalix, Madrid, 28750, Spain</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                09/2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>ما هي أقراص كلارينيز</strong><br />تحتوي أقراص كلارينيز على مزيج من عقارين (لوراتادين وكبريتات السودوإيفدرين) لوراتادين مضاد للهيستامين&nbsp;وكبريتات السودوإيفدرين مزيل للاحتقان.<br /><strong>كيف تعمل أقراص كلارينيز</strong><br />تساعد أقراص كلارينيز على التقليل من أعراض الحساسية أو البرد لديك عن طريق إيقاف تأثيرات مادةتسمى &quot;الهيستامين&quot;، والتي يُنتجها الجسم عندما تكون مصابا بالحساسية تجاه شيء ما.<br />مزيلات الاحتقان تساعد على إزالة احتقان الأنف.<br /><strong>متى ينبغي استخدام أقراص كلارينيز</strong><br />تعمل أقراص كلارينيز على تخفيف الأعراض المصاحبة لالتهاب الأنف التحسسي (حمى القش)، مثل العطس، رشح أو حكة في الأنف، والعيون، وعندما تكون مصحوبة باحتقان الأنف في البالغi والأطفال من عمر ١٢ سنة وأكثر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول أقراص كلارينيز إذا</strong><br />- كنت مصابا بالحساسية (فرط الحساسية) تجاه لوراتادين أو سودوإفدرين أو أي من المكونات الأخرى لهذا الدواء (مذكورة في القسم ٦).<br /><strong>نتيجة لوجود سودوإفدرين، لا تتناول أقراص كلارينيز</strong><br />- إذا كنت تتناول أيضا أدوية لعلاج القلب أو ضغط الدم.<br />- إذا كنت مصابا بالمياه الزرقاء (جلوكوما) أو صعوبة في التبول أو انسداد في المسالك البولية أو ارتفاع في ضغط الدم أو مرض في القلب أو الأوعية الدموية أو تاريخ للإصابة بسكتة دماغية أو فرط نشاط الغدة الدرقية.<br />- إذا كنت تتناول علاج مثبط لأكسيداز أحادي الأمi) MAO (أو تكون قد توقفت عن تناول هذا الدواء خلال الـ ١٤ يوما السابقة.<br /><strong>التحذيرات والاحتياطات</strong><br />إن بعض الحالات المرضية قد تجعلك حساسا على نحو غير&nbsp;معتاد تجاه سودوإفدرين المضاد للاحتقان الموجود في هذا الدواء. تحدث مع طبيبك أو الصيدلي قبل تناول أقراص كلارينيز إذا<br />- كنت تبلغ ٦٠ عاما أو أكثر، فمن الممكن أن يكون كبار السن أكثر&nbsp;حساسية تجاه تأثيرات هذا الدواء.<br />- كنت مصابا &lsaquo;رض السكر، أو قرحة هضمية تضييقية (قرحة تؤدي إلى ضيق في المعدة أو الأمعاء الدقيقة أو المرئ)، أو انسداد بوابي اثني عشري (انسداد الأمعاء)، أو انسداد عنق الرحم المثاD) انسداد عنق المثانة)، أو تاريخ سابق للتشنج القصبي (صعوبة التنفس نتيجة لضيق في عضلات الرئة)، أو مشاكل في الكبد أو الكلى أو المثانة.<br />- إذا كان من المقرر إجراء عملية جراحية لك لأنك قد تحتاج للتوقف عن تناول أقراص كلارينيز لعدة أيام.<br />- إذا كنت تتناول ديجيتاليس، وهو دواء يستخدم لعلاج اضرابات قلبية معينة، لأنك قد تحتاج إلى تعديل الجرعة.&nbsp;<br />- إذا كنت تتناول &alpha; -ميثيل دوبا، وميكاميلامين&nbsp;وريسيربين&nbsp;وقلويدات الخربق وجوانيثيدين لعلاج ضعط الدم، لأنك قد تحتاج إلى تعديل الجرعة.<br />- إذا كنت تتناول مزيلات للاحتقان (عن طريق الفم أو الأنف)، أو مثبطات الشهية (حبوب الحمية) أو الأمفيتامينات، لأنه عند تناولها مع أقراص كلارينيز فإن هذه الأدوية من الممكن أن تؤدي إلى ارتفاع ضغط الدم لديك.<br />- إذا كنت تتناول قلويدات الإرغوت (مثل ثنائي هيدروإرغوتامين، أو الإرغوتامi، أو ميثيل إرغوتامين( لعلاج الصداع النصفي. عند تناول هذه الأدوية إلى جانب أقراص كلارينيز فإنها قد تؤدي إلى ارتفاع ضغط الدم لديك. - إذا كنت تتنناول لينيزوليد (مضاد حيوي) أو بروموكريبتi) لعلاج العقم أو مرض باركنسون (الشلل الرعاش))، أو كابرجولi أو ليسوريد وبXجوليد (لمرض باركنسون (الشلل الرعاش)). عند تناول هذه الأدوية إلى جانب أقراص كلارينيز فإنها قد تؤدي إلى ارتفاع ضغط الدم لديك.<br />- إذا كنت تتناول مضادات الحموضة، لأنها قد تزيد من فعالية أقراص كلارينيز .<br />- إذا كنت تتناول كاولين، لأنها قد تقلل من فعالية أقراص كلارينيز .<br />- إذا كان من المقرر أن تقوم باجراء اختبارات حساسية فلا ينبغي أن تتناول أقراص كلارينيز لمدة يومين&nbsp;قبل اجراء هذه الاختبارات حيث أن هذا الدواء قد يؤثر على نتائج الاختبار.<br />اخبر طبيبك إذا كنت تعاني&nbsp;أو تم تشخيصك بأي من الحالات التالية:<br />- ضغط دم مرتفع،<br />- سرعة أو شدة ضربات القلب،<br />- عدم انتظام ضربات القلب،<br />- الشعور بالغثيان والصداع أو زيادة الصداع أثناء استخدام أقراص كلارينيز . قد ينصحك طبيبك بأن توقف علاجك. أحد مكونات أقراص كلارينيز وهو كبريتات السودوإيفدرين من الممكن أن يُساء&nbsp; استخدامه، والجرعات العالية من كبريتات السودوإيفدرين قد تكون سامة<br />يحدث بثور طفحيه حادة عامة (ِAGEP(، وهو شكل من أشكال رد الفعل الشديد للجلد، مع المنتجات المحتوية على السودوإيفيدرين في حالات معزولة. إذا لوحظت علامات وأعراض مثل الحمى، حمامي (التهاب احمراري للجلد)، أو بثور (عامة) صغيرة، يجب التوقف عن استخدام الدواء والتشاور مع الطبيب المعالج.<br /><strong>الأطفال</strong><br />لا تُعطي هذا الدواء للأطفال أقل من سن ١٢ سنة.<br /><strong>الأدوية الأخرى وأقراص كلارينيز</strong><br />أخبر طبيبك أو الصيدلي إذا كنت تتناول أو قد تناولت مؤخرا أو قد تتناول أي أدوية أخرى. ويتضمن هذا الأدوية التي يتم الحصول عليها بدون وصفة طبية<br /><strong>أقراص كلارينيز مع الكحول</strong><br />لم يظهر أن أقراص كلارينيز اضافة إلى الآثار المترتبة على المشروبات الكحولية<br /><strong>الحمل والرضاعة والخصوبة</strong><br />إذا كنت حاملا أو ترضعين&nbsp;رضاعة طبيعية أو كنت تعتقدين أنك حامل أو كنت تخططi لإنجاب طفل، استشيري طبيبك أو الصيدلي قبل تناول هذا الدواء.<br /><strong>الحمل</strong><br />لا تتناولي أقراص كلارينيز إذا كنت حاملا<br />الرضاعة الطبيعية<br />لا تتناولي أقراص كلارينيز إذا كنت ترضعين&nbsp;طبيعيا.<br />لوراتادين وسودوإفدرين يُفرزوا في حليب الأم. تم الإبلاغ عن انخفاض انتاج الحليب في الأمهات&nbsp; المرضعات عند استخدامهن لسودوإفدرين، وهو احد مكونات أقراص كلارينيز<br /><strong>القيادة واستخدام الماكينات</strong><br />من غير&nbsp;المتوقع أن تسبب أقراص كلارينيز النعاس أو قلة الانتباه عند تناولها في الجرعات الموصى بها. إلا أنه في حالات نادرة جدا قد يعاني&nbsp;بعض الأشخاص من النعاس، مما&nbsp;قد يؤثر على قدرتهم على قيادة أو استخدام الماكينات.<br /><strong>تحتوي أقراص كلارينيز على اللاكتوز والسكروز</strong><br />تحتوي أقراص كلارينيز الطويلة المفعول على لاكتوز وسكروز؛ لذلك إذا كان طبيبك قد أخبرك أنك مصاب بعدم تحمل لبعض أنواع السكر، اتصل بطبيبك قبل تناول هذا الدواء. <strong>الاختبارات المعملية</strong><br />الرياضيون الذين يتناولون أقراص كلارينيز قد تظهر لهم نتائج المنشطات إيجابية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول هذا الدواء دائماً&nbsp;كما&nbsp;أخبرك طبيبك بالضبط. يجب أن تراجع طبيبك أو الصيدلي إذا لم&nbsp;تكن متأكدا.<br /><strong>ما هي الكمية التي ينبغي أن تتناولها:</strong><br /><strong>للبالغين&nbsp;والمراهقين&nbsp;من عمر ١٢ سنة وأكثر</strong><br />الجرعة الموصى بها من أقراص كلارينيز الطويلة المفعول هي قرص واحد مرتين&nbsp;يوميا مع كوب من الماء، مع أو بدون طعام.<br />هذا الدواء للاستخدام عن طريق الفم.<br />ابتلع القرص كاملا؛ لا تسحق أو تكسر أو تمضغ القرص قبل ابتلاعه.<br />لا تتناول أقراص كلارينيز أكثر&nbsp;من الموصى به على الملصق أو تتناول الأقراص بتكرارية أكثر&nbsp;من الموصى به.<br />لا تتناول هذا الدواء لأكثر&nbsp;من ١٠ أيام مستمرة ما لم&nbsp;يخبرك الطبيب بذلك.<br /><strong>إذا تناولت أقراص كلارينيز أكثر&nbsp;مما&nbsp;ينبغي</strong><br />إذا تناولت جرعة زائدة (مفرطة)، أخبر طبيبك أو الصيدلي على الفور. تم الإبلاغ عن النعاس وسرعة ضربات القلب والصداع مع فرط الجرعة من لوراتادين، وهو أحد مكونات أقراص كلارينيز. تم الإبلاغ عن التشنجات وسرعة ضربات القلب والغثيات والعصبية مع فرط الجرعة من السودوإيفيدرين، وهو أحد مكونات أقراص كلارينيز<br /><strong>إذا نسيت تناول أقراص كلارينيز</strong><br />- إذا نسيت تناول الجرعة، تناولها جرد أن تتذكرها ثم استمر كالمعتاد.<br />- لا تتناول جرعة مضاعفة لتعويض جرعة فائتة.<br />إذا كان لديك المزيد من الأسئلة، اسأل طبيبك أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، من الممكن أن يتسبب هذا الدواء في آثار جانبية، وإن لم&nbsp;تكن تصيب الجميع. اتصل بطبيبك أو الصيدلي على الفور إذا لاحظت أي تفاعلات تجاه أقراص كلارينيز، والتي تستمر أو تكون مزعجة أو تعتقد أنها خطيرة.<br />آثار جانبية شائعة جدا (قد تصيب أكثر&nbsp;من ١ من كل ١٠ أشخاص) مرتبطة بأقراص كلارينيز ٥ مجم / ١٢٠ مجم طويلة المفعول تشمل: اضطرابات النوم.<br />آثار جانبية شائعة (قد تصيب حتى ١ من كل ١٠ أشخاص) ومرتبطة بأقراص كلارينيز ممتدة المفعول ٥ مجم / ١٢٠ مجم تشمل: العطش، العصبية، النعاس، الاكتئاب، التهيج، فقدان الشهية، الدوخة، جفاف الفم، سرعة ضربات القلب، التهاب الحلق، التهاب بطانة الأنف، والإمساك والغثيان والصداع والتعب. آثار جانبية تحدث بتكرارية أقل تشمل: الارتباك، الرعشة، زيادة التعرق، احمرارات ساخنة، تغير&nbsp;في التذوق (الطعم)، تدميع غير&nbsp;طبيعي من العينين، رنين&nbsp;في الأذن، ضربات قلب غير&nbsp;منتظمة، نزيف الأنف، التبول متكرر وغير&nbsp;طبيعي وحكة.<br /><strong>من تجربة ما بعد التسويق، تم الإبلاغ عن حالات معزولة من بثور طفحيه حادة عامة (ِAGEP(، وهو شكل من أشكال رد الفعل الشديد للجلد، مع المنتجات المحتوية على السودوإيفيدرين.</strong><br />التالي هي آثار جانبية <strong>نادرة جدا</strong> (قد تصيب حتى ١ من كل ١٠٠٠٠ شخصا) لوحظت أثناء التسويق كلارينيز: قد تم الإبلاغ عن رد فعل تحسسي بما&nbsp;في ذلك الطفح الجلدي والشرى وتورم الوجه، والدوار والتشنجات، وعدم انتظام ضربات القلب، وارتفاع ضغط الدم، والسعال، وضيق في الشعب الهوائية ومشاكل في الكبد، وصعوبة التبول، وفقدان الشعر.<br /><strong>بعض الآثار الجانبية التي تم الإبلاغ عنها فقط للوراتادين في التجارب السريرية وخلال فترة ما بعد التسويق تشمل زيادة الشهية، والطفح الجلدي، واضطراب في المعدة</strong><br /><strong>الإبلاغ عن الآثار الجانبية</strong><br />إذا أصبت بأي أعراض جانبية، تحدث مع طبيبك أو الصيدلي. وهذا يشمل أي آثار جانبية محتملة وغير&nbsp;مذكورة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك أن تساعد على توفير&nbsp;مزيد من المعلومات حول سلامة هذا الدواء.<br /><strong>للإبلاغ عن أي أعراض جانبية<br />المركز الوطني للتيقظ والسلامة الدوائية:<br />مركز الإتصال الموحد: 19999<br />npc.drug@sfda.gov.sa :البريد الالكتروني<br />&nbsp;https://ade.sfda.gov.sa/ :الموقع الالكتروني</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- احفظ هذا الدواء بعيدا عن متناول ورؤية الأطفال.<br />- يحفظ في درجة حرارة لا تزيد عن ٢٥ درجة مئوية. يخزن في عبوته الأصلية من أجل حمايته من الرطوبة. لا تُجمد الدواء.<br />- لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة والشريط بعد تاريخ الإنتهاء &quot;EXP&quot;. تاريخ الانتهاء يشير&nbsp;إلى آخر يوم من ذلك الشهر.<br />- لا تتناول هذا الدواء إذا لاحظت أي تغير&nbsp;في شكل الأقراص.<br />- لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم&nbsp;تعد تستخدمها. سوف تساعد هذه التدابير&nbsp;على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- المادة الفعالة في أقراص كلارينيز الطويلة المفعول هي لوراتادين ٥ مجم وكبريتات السودوإيفدرين ١٢٠ مجم.<br />- المكونات الأخرى هي: لب القرص - لاكتوز أحادي الهيدرات؛ نشا الذرة؛ بوفيدون؛ ستيارات المغنيسيوم؛ غلاف القرص- السنط (الأكاشيا)؛ كبريتات الكالسيوم لا مائي&nbsp;كبريتات الكالسيوم ثنا الهيدرات؛ شمع كرنوبا؛ سيلولوز مكروي التبلور؛ حمض الأوليك؛ كولوفونيوم؛ مسحوق الصابون؛ سكروز؛ تلك؛ ثاني&nbsp;أكسيد التيتانيوم؛ شمع العسل الأبيض. وزين</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص كلارينيز ٥ مجم / ١٢٠ مجم هي أقراص مستديرة، بيضاء، طويلة المفعول. و هي متوفرة في شرائط في عبوات بأحجام ،١ ،٧ ،١٠ ،١٤ ،٢٠ ،٢٨ ،٣٠ ،٥٠ ١٠٠ قرص. ليس من الضروري أن يتم تسويق جميع الأحجام.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>باير كونسيومر كt أ.ج. بازل - سويسرا يتم التصنيع و إصدار التشغيلة من قبل: مصنع ساج اس. ال. يو، سان اوغستV دو جواداليكس، مدريد، ،٢٨٧٥٠ اسبانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر موافقة على هذه النشرة في سبتمبر.٢٠١٧
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CLARINASE®Repetabs 5 mg/120 mg prolonged-release tablets 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each prolonged-release tablet contains 5 mg loratadine and 120 mg pseudoephedrine sulphate. 
Excipients with known effect: The quantities of sucrose and lactose monohydrate in each prolongedrelease tablet are 173.23 mg and 156.80 mg respectively. 
For the full list of excipients, see section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prolonged-release tablet: Round, biconvex, lustrous, white, coated tablet 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clarinase Repetabs is indicated for the symptomatic treatment of seasonal allergic rhinitis when accompanied by nasal congestion in adults and children 12 years of age and over.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology Adults and children 12 years of age and over: One Clarinase Repetabs prolonged-release tablet twice daily with a glass of water. The duration of treatment should be kept as short as possible and should not be continued after the symptoms have disappeared. It is advisable to limit treatment to about 10 days, as during chronic administration the activity of pseudoephedrine may diminish. After improvement of the congestive condition of the mucosae of the upper airway, treatment may be maintained with loratadine alone, if necessary. Paediatric population The safety and efficacy of Clarinase Repetabs in children below the age of 12 years have not been established. No data are available. Clarinase Repetabs are not recommended for use in children below the age of 12 years. Elderly patients The combination product should not be administered to patients above 60 years of age. Patients 60 years or older are more likely to experience adverse reactions to sympathomimetic medications (see section 4.4). Patients with renal or hepatic impairment The combination product should not be used in patients with impaired renal or hepatic function (see section 4.4). Method of administration Oral use. The prolonged-release tablet must be swallowed entirely (without crushing, breaking or chewing it). The prolonged-release tablet may be taken without regard to mealtime.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section 6.1, or to adrenergic 
medicinal products. 
As Clarinase Repetabs contains pseudoephedrine, it is also contraindicated in patients who are receiving 
irreversible monoamine oxidase (MAO) inhibitor therapy or during the 2 weeks following the stopping of
such treatment, and in patients with: 
- narrow-angle glaucoma, 
- urinary retention, 
- cardiovascular diseases such as ischaemic heart disease, tachyarrhythmia and severe hypertension, 
- hyperthyroidism, 
- a history of haemorhagic stroke or with risk factors which could increase the risk of haemorhagic 
stroke. This is due to the alpha-mimetic activity of pseudoephedrine, in combination with other 
vasoconstrictors such as bromocripitine, pergolide, lisuride, cabergoline, ergotamine, 
dihydroergotamine or any other decongestant medication used as a nasal decongestant, either by oral 
route or by nasal route (such as phenylpropanolamine, phenylephrine, ephedrine, oxymetazoline, 
naphazoline). 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not exceed the recommended dosage and the duration of treatment (see section 4.2). Patients of 60 years or older are more likely to experience adverse reactions to sympathomimetic medications. The safety and efficacy of the combination have not been established in this population, and there are insufficient data to give adequate dose recommendations. The combination product should not be used in patients above 60 years of age. Renal or hepatic impairment: The safety and efficacy of the combination have not been established in patients with impaired renal or hepatic function, and there are insufficient data to give adequate dose recommendations. The combination product should not be used in patients with impaired renal or hepatic function. Patients should be informed that the treatment should be discontinued in case of hypertension, tachycardia, palpitations or cardiac arrhythmias, nausea or any other neurologic sign (such as headache or increased headache). Central nervous system stimulation with convulsions or cardiovascular collapse with accompanying hypotension may be produced by sympathomimetic amines. These effects may be more likely to occur in children, the elderly, or in cases of overdose (see section 4.9). Acute generalized exanthematous pustulosis (AGEP), a form of severe skin reaction, may occur with pseudoephedrine-containing products in isolated cases. If signs and symptoms such as fever, erythema, or small (generalized) pustules are observed, patients should discontinue to use the drug and consult their physician. Caution should be exercised in patients receiving digitalis, those with cardiac arrhythmias, hypertension, a history of myocardial infarction, diabetes mellitus, bladder neck obstruction, or positive anamnesis of bronchospasm. Use with caution in patients with stenosing peptic ulcer, pyloroduodenal obstruction and obstruction of the vesical cervix. Oral administration of pseudoephedrine at the recommended dose can cause other sympathomimetic effects, such as increased blood pressure, tachycardia or manifestations of central nervous system excitation. Concomitant administration of sympathomimetics and reversible MAO inhibitors (such as linezolide [non-selective] and moclobemide [MAO-A selective] are not recommended. Caution should also be exercised in patients being treated with other sympathomimetics, including decongestants, anorexogenics or amphetamine-type psychostimulants, antihypertensive agents, tricyclic antidepressants and other antihistamines. Caution should be exercised in patients who are currently being treated with ergot alkaloid vasoconstrictors. As with other CNS stimulants, pseudoephedrine sulphate carries the risk of abuse. Increased doses may ultimately produce toxicity. Continuous use can lead to tolerance resulting in an increased risk of overdosing. Depression may follow rapid withdrawal. Perioperative acute hypertension can occur if volatile halogenated anaesthetics are used during treatment with indirect sympathomimetic agents. Therefore, if surgery is scheduled, it is preferable to discontinue treatment 24 hours before anaesthesia. Athletes should be informed that treatment with pseudoephedrine could lead to positive dope-tests. This medicinal product contains lactose and sucrose; thus patients with rare hereditary problems of fructose, galactose intolerance, the Lapp lactase deficiency, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. The administration of Clarinase Repetabs should be discontinued at least 48 hours before skin tests since antihistamines may prevent or reduce otherwise positive reactions to dermal reactivity index</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When administered concomitantly with alcohol, loratadine has no potentiating effects as measured by psychomotor performance studies. CYP3A4 and CYP2D6 inhibitors have been shown to increase loratadine and desloratadine exposure. However, due to the wide therapeutic index of loratadine, no clinically relevant interactions are expected and none were observed with co-administration of erythromycin, ketoconazole and cimetidine in the conducted clinical trials (see section 5.2). Concurrent administration of monoamine oxidase inhibitors (reversible or irreversible) and sympathomimetic medicines can cause critical hypertension reactions. Sympathomimetic medicines may reduce the effect of antihypertensive medicines. The following combinations are not recommended: Bromocriptine, cabergoline, lisuride, pergolide: risk of vasoconstriction and increase in blood pressure. Dihydroergotamine, ergotamine, methylergometrine: risk of vasoconstriction and increase in blood pressure. Reversible and irreversible MAO inhibitor(s): risk of vasoconstriction and increase in blood pressure. Other vasoconstrictors used as nasal decongestant, by oral or nasal route, (such as phenylpropanolamine, phenylephrine, ephedrine, oxymetazoline, naphazoline): risk of vasoconstriction. Antacids increase the rate of pseudoephedrine sulphate absorption, kaolin decreases it. Paediatric population Interaction studies have only been performed in adults</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy Neither loratadine nor the combination of loratadine and pseudoephedrine were teratogenic in animal studies. The safe use of Clarinase Repetabs during pregnancy has not been established; however experience from a large number of exposed pregnancies in humans does not reveal any increase in the frequency of malformations as compared to the incidence in the general population. Because animal reproduction studies are not always predictive of human response, and due to the vasoconstrictive properties of pseudoephedrine, Clarinase Repetabs should not be used during pregnancy. Breast-feeding Physico-chemical data suggest excretion of loratadine and pseudoephedrine/metabolites in human milk. Decreased milk production in nursing mothers has been reported with pseudoephedrine. A risk to the newborns/infants cannot be excluded. Therefore Clarinase Repetabs should not be used during breast-feeding. Fertility There are no data available on male and female fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clarinase Repetabs has no or negligible influence on the ability to drive and use machines. In clinical trials that assessed driving ability, no impairment occurred in patients receiving loratadine. However, some people very rarely experience drowsiness, which may affect their ability to drive or use machines. It is not expected that pseudoephedrine sulphate impairs psychomotor performance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tabulated list of adverse reactions The following adverse reactions reported during clinical trials in excess of placebo for 5 mg/120 mg prolonged-release tablets are listed in the following table by System Organ Class. Frequencies are defined as very common (&gt; 1/10); common (&gt; 1/100, &lt; 1/10); uncommon (&gt; 1/1000, &lt; 1/100); rare (&gt; 1/10,000, &lt; 1/1000); very rare (&lt; 1/10,000); and not known (cannot be estimated from the available data). System Organ Class Frequency Category Adverse Reactions Metabolism and nutrition disorders Common Thirst Psychiatric disorders Common Nervousness, somnolence, depression, agitation, anorexia Very Common Insomnia Nervous system disorders Uncommon Confusion, tremor, increased sweating, hot flushes, taste perversion Common Dizziness, Eye disorders Uncommon Abnormal lacrimation Ear and labyrinth disorders Uncommon Tinnitus Cardiac disorders Uncommon: Palpitation Common Tachycardia Respiratory, thoracic and mediastinal disorders Uncommon: Epistaxis Common Pharyngitis, rhinitis Gastrointestinal disorders Common Constipation, nausea, dry mouth Skin and subcutaneous tissue disorders Uncommon Pruritus Renal and urinary disorders Uncommon Micturition frequency and disorder General disorders and administration site conditions Common Headache, fatigue Other adverse reactions reported during the post-marketing period are listed in the following table. System Organ Class Frequency Category Adverse Reactions Immune system disorders Very rare Hypersensitivity reactions (such as anaphylaxis, rash, urticaria, and angioedema) Nervous system disorders Very rare Vertigo, convulsions Cardiac disorders Very rare Cardiac arrhythmias Vascular disorders Very rare Hypertension Respiratory, thoracic and mediastinal disorders Very rare Cough, bronchospasm Hepatobiliary disorders Very rare Abnormal hepatic function Skin and subcutaneous tissue disorders Very rare Alopecia Renal and urinary disorders Very rare Urinary retention Other adverse reactions that were only reported for loratadine in clinical trials and during the postmarketing period include increased appetite, rash and gastritis. From post-marketing experience, isolated cases of acute generalized exanthematous pustulosis (AGEP), a form of severe skin reaction, have been reported with pseudoephedrine-containing products. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. To report any side effect(s) National Pharmacovigilance and Drug Safety Center (NPC). Fax: + 966 - 11 - 205 - 7662. Call NPC at +966 - 11 - 2038222, Ext.: 2317 - 2356 - 2353 - 2354 - 2334 - 2340. Toll - free: 8002490000. E - mail: npc.drug@sfda.gov.sa. Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms of overdose Symptoms of overdose are mostly of a sympathomimetic nature, except for slight sedation that can be caused by loratadine at doses many times higher than the recommended dose. Symptoms may vary from CNS depression (sedation, apnoea, diminished mental alertness, cyanosis, coma, cardiovascular collapse) to CNS stimulation (insomnia, hallucination, tremors, convulsions) with possible fatal outcome. Other symptoms may include: headache, anxiety, micturition difficulty, muscle weakness and tenseness, euphoria, excitement, respiratory failure, cardiac arrhythmias, tachycardia, palpitations, thirst, perspiration, nausea, vomiting, precordial pain, dizziness, tinnitus, ataxia, blurred vision and hypertension or hypotension. CNS stimulation is particularly likely in children, as are atropine-like symptoms (dry mouth, fixed and dilated pupils, flushing, hyperthermia, and gastrointestinal symptoms). Some patients may present with a toxic psychosis with delusions and hallucinations. Management of overdose In the event of overdosage, start symptomatic and supportive treatment immediately and maintain it for as long as necessary. Adsorption of active substance remaining in the stomach may be attempted by administration of active charcoal suspended in water. Perform gastric lavage with physiologic saline solution, particularly in children. In adults, tap water can be used. Remove as much as possible of the amount administered before the next instillation. Loratadine is not removed by haemodialysis and it is not known if loratadine is eliminated by peritoneal dialysis. After emergency treatment, continue to monitor the patient medically. Treatment of the pseudoephedrine overdosage is symptomatic and supportive. Stimulants (analeptics) must not be used. Hypertension can be controlled with an alpha-blocking agent and tachycardia with a beta-blocking agent. Short acting barbituates, diazepam or paraldehyde may be administered to control seizures. Hyperpyrexia, especially in children, may require treatment with tepid water sponge baths or hypothermia blanket. Apnoea is treated with respiratory assistance</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antihistamines &ndash; H1 antagonist, ATC code: R06A X13. Pharmacotherapeutic group: Nasal decongestants for systemic use group, ATC code: R01BA52. Mechanism of action Loratadine is a tricyclic antihistamine with selective, peripheral H1-receptor activity. Pseudoephedrine sulphate (d-isoephedrine sulphate) is a sympathomimetic agent with mostly &alpha;mimetic activity in comparison with the &beta;-activity. Pseudoephedrine sulphate provides a nasal decongestant effect after oral administration due to its vasoconstrictive action. It has an indirect sympathomimetic effect due primarily to the release of adrenergic mediators from the post-ganglionic nerve endings. Pharmacodynamic effects The pharmacodynamics of Clarinase Repetabs tablets are directly related to that of its components. Loratadine has no clinically significant sedative or anticholinergic properties in the majority of the population and when used at the recommended dosage. During long-term treatment there were no clinically significant changes in vital signs, laboratory test values, physical examinations or electrocardiograms. Loratadine has no significant H2-receptor activity. It does not inhibit norepinephrine uptake and has practically no influence on cardiovascular function or on intrinsic cardiac pacemaker activity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&bull; Loratadine Absorption Loratadine is rapidly and well-absorbed. Concomitant ingestion of food can delay slightly the absorption of loratadine but without influencing the clinical effect. The bioavailability of loratadine and of the active metabolite are dose proportional. Increase in plasma concentrations of loratadine has been reported after concomitant use with ketoconazole, erythromycin, and cimetidine in controlled trials, but without clinically significant changes (including electrocardiographic). Distribution Loratadine is highly bound (97 % to 99 %) and its active major metabolite desloratadine (DL) moderately bound (73 % to 76 %) to plasma proteins. In healthy subjects, plasma distribution half-lives of loratadine and its active metabolite are approximately 1 and 2 hours, respectively. Biotransformation After oral administration, loratadine undergoes an extensive first pass metabolism, mainly by CYP3A4 and CYP2D6. The major metabolite-desloratadine (DL) is pharmacologically active and responsible for a large part of the clinical effect. Loratadine and DL achieve maximum plasma concentrations (Tmax) between 1&ndash; 1.5 hours and 1.5&ndash;3.7 hours after administration, respectively. Elimination Approximately 40 % of the dose is excreted in the urine and 42 % in the faeces over a 10 day period and that, mainly in the form of conjugated metabolites. Approximately 27 % of the dose is eliminated in the urine during the first 24 hours. Less than 1 % of the active substance is excreted unchanged in active form, as loratadine or DL. The mean elimination half-lives are 8.4 hours (range = 3 to 20 hours) for loratadine and 28 hours (range = 8.8 to 92 hours) for the active metabolite. Renal impairment In patients with chronic renal impairment, both the area under the curve (AUC) and peak plasma levels (Cmax) increased for loratadine and its active metabolite as compared to the AUCs and peak plasma levels (Cmax) of patients with normal renal function. The mean elimination half-lives of loratadine and its active metabolite were not significantly different from those observed in normal subjects. Haemodialysis does not have an effect on the pharmacokinetics of loratadine or its active metabolite in subjects with chronic renal impairment. Hepatic impairment In patients with chronic alcoholic liver disease, the AUC and peak plasma levels (Cmax) of loratadine were double while the pharmacokinetic profile of the active metabolite was not significantly changed from that in patients with normal liver function. The elimination half-lives for loratadine and its metabolite were 24 hours and 37 hours, respectively, and increased with increasing severity of liver disease. Elderly The pharmacokinetic profile of loratadine and its metabolites is comparable in healthy adult volunteers and in healthy geriatric volunteers. &bull; Pseudoephedrine sulphate Absorption After oral administration, pseudoephedrine sulphate is rapidly and completely absorbed. Onset of action occurs within 30 minutes and a dose of 60 mg has a decongestive action lasting for 4 to 6 hours. Food may increase the amount of loratadine absorbed, but without clinically significant results. This is not observed with pseudoephedrine. Distribution Pseudoephedrine is presumed to cross the placenta and the haematoencephalic barrier. The active substance is excreted in breast milk of lactating women. Biotransformation Pseudoephedrine sulphate undergoes incomplete hepatic metabolism by N-demethylation to an inactive metabolite. Elimination Its elimination half-life in humans, at an approximate urinary pH of 6, ranges from 5 to 8 hours. The active substance and its metabolite are excreted in urine, 55-75 % of the administered dose is excreted unchanged. The rate of excretion is accelerated and the duration of action decreased in acidic urine (pH5). In case of alkalinization of the urine, a partial resorption takes place.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data for loratadine reveal no special hazard for humans based on conventional studies of safety, pharmacology, repeated dose toxicity, genotoxicity and carcinogenicity. Toxicity for the combination: In acute and multiple-dose studies, the combination of loratadine/pseudoephedrine sulphate exhibited a low order of toxicity. The combination was not more toxic than their individual components, and observed effects were generally related to the pseudoephedrine component. In reproductive toxicity studies of loratadine, no teratogenic effects were observed. However, prolonged parturition and reduced viability of offspring were observed in rats at plasma levels (AUC) 10 times higher than those achieved with clinical doses. During reproductive toxicity studies, the combination of loratadine/pseudoephedrine was not teratogenic when administered orally to rats at doses up to 150 mg/kg/day (30 times the proposed clinical dose) and rabbits at doses up to 120 mg/kg/day (24 times the proposed clinical dose).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>6.1 List of excipients Core: Lactose monohydrate Maize starch Povidone (E1201) Magnesium stearate Coating: Acacia (E414) Calcium sulphate anhydrous (E516) Calcium sulphate dihydrate (E516) Carnauba wax (E903) Microcrystalline cellulose Oleic acid Colophonium Soap powder Sucrose Talc (E553b) Titanium dioxide (E171) White beeswax (E901) Zein</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25&deg;C. Store in the original blister packaging in order to protect from moisture. Do not freeze.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister strip consisting of a clear, transparent PVC-PCTFE film (PVC in contact with product) and a lidding of aluminium foil with vinyl heat seal coating. The blister strips are enclosed in cartons in pack sizes of 1, 7, 10, 14, 20, 28, 30, 50 and 100 tablets. Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bayer Consumer Care AG, 
Basel - Switzerland.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 09/2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>